High-sensitivity troponin T for prediction of left ventricular function and infarct size one year following

Sebastian Johannes Reinstadler1, Hans-Josef Feistritzer1, Gert Klug1

  • 1Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck Austria.

Insights

Early high-sensitivity cardiac troponin T (hs-cTnT) levels accurately predict long-term heart function and infarct size after ST-elevation myocardial infarction (STEMI). hs-cTnT alone is sufficient for prognosis, outperforming combinations with other biomarkers.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Myocardial Infarction

Background:

  • Limited data exists on the relationship between high-sensitivity cardiac troponin T (hs-cTnT) and long-term outcomes post-ST-elevation myocardial infarction (STEMI).
  • Assessing long-term myocardial function and infarct size is crucial for patient management after STEMI.

Purpose of the Study:

  • To evaluate early hs-cTnT concentrations for predicting myocardial function and infarct size.
  • To assess these parameters using cardiac magnetic resonance imaging (CMR) one year after STEMI.

Main Methods:

  • Sixty-six STEMI patients undergoing primary percutaneous coronary intervention (PCI) were studied.
  • Serial hs-cTnT, creatine kinase (CK), hs-CRP, and LDH levels were measured post-PCI.
  • Cardiac magnetic resonance imaging (CMR) was performed within the first week and at 12 months.

Main Results:

  • Peak hs-cTnT concentrations strongly correlated with left ventricular ejection fraction (LVEF) and infarct size (IS) at baseline and 12 months.
  • Peak hs-cTnT achieved an AUC of 0.82 for predicting reduced LVEF and 0.89 for large IS at 12 months.
  • Combining hs-cTnT with CK, hs-CRP, or LDH did not significantly improve predictive value for LVEF or IS.

Conclusions:

  • Serial and peak hs-cTnT concentrations are reliable predictors of long-term LVEF and IS in stable STEMI patients after successful PCI.
  • hs-cTnT alone provides sufficient prognostic information, negating the need for additional biomarkers like CK, hs-CRP, or LDH.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
451
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.7K